Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc is positioned for a positive financial outlook due to anticipated revenue growth from its Signatera test, which has shown impressive quarterly gains with a 54% year-over-year increase in molecular residual disease volumes. The company's strong performance in the most recent quarter included an approximately $80 million revenue beat and a significant raise in its 2025 revenue guidance by $160 million. Furthermore, Natera's efforts to expand reimbursement coverage for additional cancer types could enhance average selling prices and bolster operating cash flow, contributing to overall financial strength.

Bears say

Natera Inc faces significant challenges that contribute to a negative outlook, primarily due to anticipated erosion of margins stemming from pricing reductions as more commercial payors become involved and the addressable market expands to encompass average-risk patients. Furthermore, potential setbacks related to regulatory issues, reimbursement complications, or delays in product launches could adversely impact financial performance and lead to a decline in stock value. The company's expansion efforts in international markets also face headwinds from the lack of compelling data and possible obstacles related to pricing and reimbursement, complicating the overall growth trajectory.

Natera (NTRA) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 15 analysts, Natera (NTRA) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $249.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $249.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.